共 11 条
- [5] Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α Gene Therapy, 2005, 12 : 140 - 146
- [7] MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain Cancer Immunology, Immunotherapy, 2004, 53 : 525 - 532